However, as human lipolysis is mainly mediated by the other β-adrenoreceptors, ADRB3 agonists failed as anti-obesity therapies (Arch, 2011, Lafontan and Berlan, 1993, Ursino et al., 2009). The gene discussed is ADRB3; the disease is obesity disorder.